Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Moving higher and still over sold. Check market 23 million.
An empty drum makes the most noise.
It appears attorney's are using the same reasoning basis and case study's for each suit (insert name here). The judge should sanction just on a case of incompetency.
Ladenburg Thalmann 2016 Healthcare Conference
Event: Presentation by Christopher U. Missling, PhD, President and Chief Executive Officer
Date/Time: Tuesday, September 27, 2016
2:00 p.m. ET
Location: Odeon-Track 2, Sofitel Hotel, New York, NY
Dr. Missling’s presentation is scheduled to take place on Tuesday, September 27, 2016 at 2:00 pm Eastern Time in Odeon-Track 2. The conference will be held at the Sofitel Hotel in New York City.
A live audio webcast of the presentation will be available on the conference website at http://wsw.com/webcast/ladenburg2/avxl. Investors may also view an archived version of the presentation on www.anavex.com.
And if the results had been found "unambiguously good" after the sell off share price would have soon recovered. There was evidence the 7 or so on A-273 alone saw improvement. For next data set we need to see more of this or even better yet a ever so slight upward arc of the A-273 Plus population. Share price should then recover.
Superbug MRSA spreading through tainted poultry. With all the drug resistant strains world wide Brilacidin when approved could be a first line defense.imo
https://www.washingtonpost.com/news/to-your-health/wp/2016/09/21/superbug-mrsa-may-be-spreading-through-tainted-poultry/
Mizuho. I was wondering if this may have a connection with Japanese investors.
Monday, September 19, 2016 - Cellceutix will present, and participate in multiple panel discussions, at the 14th Annual Discovery on Target Conference in Boston. The Company's main presentation is titled, "Prurisol: A New Small Molecule under investigation for the treatment of Psoriasis", and will be made available in the Investors section of the cellceutix.com website.
Investor Presentation 2016-0912 Final
http://content.stockpr.com/archtherapeutics/media/a615ba3d0a9c00b0e77d846e84303000.pdf
It's a fair bet there will be a buyer. It's the who that's unknown. I'm actually hoping for such a positive response there's a bidding war.
Todays presentation Audio link:
http://cellceutix.com/wp-content/uploads/2014/06/CTIX-Newsmakers-In-Biotech-Conference-2016.m4a
Ashcroft law Firm read the complaint and came to bat. Company pipeline Prurisol, Kevetrin, Brilacidin and the host of treatable indications.
I know I am. Think Cellceutix is clearly getting traction.
Dr Bertolino called for UP trial update next month. Positive trial here will prove Brilacidin an anti-inflammatory as well as antibiotic.
In the audio Dr Bertolino said we will "fire Up" Prurisol Phase2 study in a couple months. Data by the end of next summer for use in a shortened Phase3 study.
Thanks Karin. Listened to the audio in conjunction with viewing the slides. DR Bertolino is well versed and absolutely has a great plan bringing Prurisol in #1 spot...the easy stuff first. Cellceutix is building a breakout plan.
Agree I see no pullback in regards to K P2a.
Kevetrin
Upcoming Phases 2a Clinical Trial in Late-Stage Ovarian Cancer
• Combination therapy
• Kevetrin (starting dose 250 mg/m2) 3 times/ week with dose escalation
• Doxil® (doxorubicin hydrochloride liposome infusion) every 4 weeks
"Terrence W. Norchi, MD, CEO, and Richard Davis, CFO, are scheduled to present on Monday, September 12th at 4:40 PM ET in Holmes 1 and will be available to participate in one-on-one meetings with investors who are registered to attend the conference"
Hopefully we attract some deep pockets.
Nice move UP today. Shows strength.
Mast presenting Rodman & Renshaw Tuesday Sept13 11:40am.
http://masttherapeutics.com/investors/news/?releaseid=2198877
Use as a safe non-steroidal anti-inflammatory would put Brilacidin into a huge market.
I look for straight Prurisol buy out and a B platform partner. Brilacidin seems to be the gift that keeps on giving.
Dr Bertolino "Our expectations are to initiate the trial late in the third quarter or early in the fourth quarter with top-line results in the second quarter of 2017".
"A new oral drug that delivers substantial efficacy should command considerable market value and further attract the attention of pharmas looking to expand their dermatology offerings. I believe that Prurisol has that potential and that a refined second successful Phase 2 trial would further anchor the value that we already appreciate."
Yes I agree, after review of safety and PASI scores buy out second quarter seems likely.
Besides being faster it's important to also weigh the broader benefit of AC5 over competition.
"Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision. Because it is not sticky or glue-like, it is ideal for use in the laparoscopic setting – a challenge for much of the competition. Furthermore, it is transparent, enabling a surgeon to operate through it in order to prophylactically stop bleeding as it starts – we call this Crystal Clear Surgery™.
Yes POC has been in full swing for close to 2 months now and I agree somebody knows something. I believe B-UP trial is huge for the company and our canary in the coal mine. This trial would tell us early on that as a anti-inflammatory Brilacidin works. Per July18 PR "Both the patient and the site staff have been amazed how the study drug works as all the symptoms decreased significantly within the 1st week of treatment."
The statement "interested in co-developing" makes it sound like a K partner could jump in at any time.
Palm reading that's funny...does the M stand for money or misery here..
Since were throwing out percentages, 81% of cancer trials fail. Clean safety profile is half the battle imo.
From what I've gathered a lot AZ trials fail due to safety concerns even death. In this Phase 2a trial further safety data was gathered which again showed drug as being safe which is a high hurdle to over come. The bar is set low for efficacy so for us to see a positive response up to 31 weeks and a great safety profile is huge in AZ trials.
Most AZ trials fail due to SAE's. Alzheimers is a tough nut to crack and all we can hope for is better then SOC. A-273 has a different MOA so we hope. Trial has shown so far better than SOC. As a shareholder I'M hopefull.
"will be reporting new data to investors as it becomes available."
They plan to just release future news. I like this.
The initial start to sell off right at the time PR was issued caused a cascading effect taking out stops all the way down. Who really had a chance to decipher the charts while their money is flying out of accounts. What I look for now is a partnership. This will be our sign.
Thanks Karin. Yes we see that with ctix. Good pr and price drops.
Exactly basparks. Give us shareholders timely updates. IMO these conferences while good for showing progression to others in the field do little for share holder value. Upcoming material events is what brings in new investors and value.
The fix was in. We clearly need a big pharma partnership.
Todays poster proof positive.
*MMSE mean scores maintained over 31 weeks
*Statistical analysis of MMSE revealed no other grouping factors (sex,
ApoE4, age, donepezil, baseline value) influencing the analysis
*Statistical analyses also revealed overall ?-MMSE-scores
maintained at the same level and effects were confirmed with
Bayesian inference calculations
*In a disease state where progression is invariable over time, a stable
MMSE score is considered a positive outcome.
Conclusions.
"For cognitive assessment using the Cogstate test batteries, ANAVEX
2-73 continues to show benefits over baseline at 17 weeks and 31
weeks. ANAVEX 2-73 related improvement in psychomotor function,
attention and working memory are preserved through 17 weeks and 31
weeks of treatment. Repeated-measures ANOVA reveals that Cogstate
values maintained the baseline values through week 31.
Mathematical modeling of the pharmacodynamic results is in progress".
Exactly, shorts had plan set in place before news could be disseminated.
Disease stable to 31 weeks, very bullish. So far so good.